Novel targets in the management of pneumonia.
Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.
Díaz
Luis A
LA
Geisinger Health System and Fundación Universitaria de Ciencias de la Salud, Hospital de San José, Bogotá DC, Colombia.
Mortensen
Eric M
EM
Anzueto
Antonio
A
Restrepo
Marcos I
MI
D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D003422:Critical Care / Q000379:methods; D016503:Drug Delivery Systems; D006801:Humans; D011014:Pneumonia / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000890:Anti-Infective Agents